Insights On Drug Development

  1. From First-In-Human To Proof-Of-Concept — Quicker, Smarter, Streamlined 10/14/2025

    Explore examples of smarter SAD/MAD trial designs including multi-part and hybrid protocols, regulatory foresight, recruitment considerations, and operational strategies that keep programs moving.

  2. Top 8 Considerations For Choosing A PDX Model 10/7/2025

    To guide your decision-making, we’ve outlined the top 10 criteria to consider when evaluating PDX models for your next oncology research or drug development program.

  3. Sniffing Out Solutions In The Nasal Drug Delivery Revolution 10/7/2025

    As research continues to advance, nasal drug delivery stands at the intersection of innovation and practicality — offering a unique opportunity to expand therapeutic reach while rethinking how medicines are administered and experienced.

  4. Human iPSC Modeling, Drug Screening For Neurodegenerative Disorders 10/3/2025

    iPSC technology enables genetically engineered human cells for neurotoxicity and neuroprotection assays, offering scalable disease models for drug discovery and toxicity screening.

  5. What Are The Keys To Making Rare Disease Drug Development Sustainable? 9/30/2025

    This roundtable weaves together diverse perspectives, providing a multifaceted look at what it will take to create a sustainable path forward in rare disease drug development.

  6. Utilizing Flow Cytometry For Humoral Immunogenicity Testing: Cell & Gene Therapy 9/29/2025

    Discover strategies to overcome immunogenicity challenges in cell and gene therapies, with a focus on harnessing flow cytometry to enhance ADA and NAb assay development, strengthen validation, and ensure regulatory readiness.

  7. Streamlining Biologics Development: Leveraging Small-Scale Studies For Greater Efficiency 9/25/2025

    Uncover how a data-driven approach to small-scale studies not only accelerates development timelines but also enhances decision-making and resolves full-scale manufacturing challenges across diverse biologic modalities.

  8. Overcoming Unique Client Challenges With A Strong Collaborative Partnership 9/23/2025

    Through close collaboration, proactive communication, and agile project management, our partnership accelerated an oncology program and helped overcome complex preclinical hurdles.

  9. Advancing ADC Development: Overcoming Preclinical Challenges 9/23/2025

    Learn how to accelerate the journey of ADC candidates from early discovery to clinical development, enhancing the success rate of translating preclinical discoveries into effective cancer treatments.

  10. BxPC-3: Evaluating Responses To Standard Therapeutic Agents 9/23/2025

    Review multiple studies utilizing the BxPC-3 human pancreatic cancer model in subcutaneous (SC) NSG and NSG-dKO mouse models, evaluating a range of standard agents, vehicles, and delivery methods.